153 related articles for article (PubMed ID: 11834531)
1. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
de Beer F; Stalenhoef AF; Hoogerbrugge N; Kastelein JJ; Gevers Leuven JA; van Duijn CM; Havekes LM; Smelt AH
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):294-9. PubMed ID: 11834531
[TBL] [Abstract][Full Text] [Related]
2. Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism.
Sijbrands EJ; Hoffer MJ; Meinders AE; Havekes LM; Frants RR; Smelt AH; De Knijff P
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2722-9. PubMed ID: 10559017
[TBL] [Abstract][Full Text] [Related]
3. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia.
Evans D; Seedorf U; Beil FU
Clin Genet; 2005 Oct; 68(4):369-72. PubMed ID: 16143024
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
Mahley RW; Huang Y; Rall SC
J Lipid Res; 1999 Nov; 40(11):1933-49. PubMed ID: 10552997
[TBL] [Abstract][Full Text] [Related]
8. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
Henneman P; van der Sman-de Beer F; Moghaddam PH; Huijts P; Stalenhoef AF; Kastelein JJ; van Duijn CM; Havekes LM; Frants RR; van Dijk KW; Smelt AH
Eur J Hum Genet; 2009 May; 17(5):620-8. PubMed ID: 19034316
[TBL] [Abstract][Full Text] [Related]
9. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance.
de Villiers WJ; van der Westhuyzen DR; Coetzee GA; Henderson HE; Marais AD
Arterioscler Thromb Vasc Biol; 1997 May; 17(5):865-72. PubMed ID: 9157949
[TBL] [Abstract][Full Text] [Related]
10. Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-->Cys) compared.
Zhao SP; Smelt AH; Van den Maagdenberg AM; Van Tol A; Vroom TF; Gevers Leuven JA; Van der Laarse A; Van 't Hooft FM
Clin Chem; 1994 Aug; 40(8):1559-66. PubMed ID: 8044997
[TBL] [Abstract][Full Text] [Related]
11. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
Huang Y; Rall SC; Mahley RW
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
[TBL] [Abstract][Full Text] [Related]
13. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus.
Eto M; Watanabe K; Sato T; Makino I
J Clin Endocrinol Metab; 1989 Dec; 69(6):1207-12. PubMed ID: 2584356
[TBL] [Abstract][Full Text] [Related]
15. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
[TBL] [Abstract][Full Text] [Related]
17. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
18. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
20. The D9N, N291S and S447X variants in the lipoprotein lipase (LPL) gene are not associated with Type III hyperlipidemia.
Evans D; Beil FU
BMC Med Genet; 2007 Aug; 8():56. PubMed ID: 17727701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
